# This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response

> **NCT06851169** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 58 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Cohort 1: Neoadjuvant therapy (benmelstobart combined with anlotinib)
- **DRUG:** Cohort 2: Neoadjuvant therapy (benmelstobart only)

## Key facts

- **NCT ID:** NCT06851169
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06851169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06851169, "This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06851169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*